IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Inclusion Criteria: * Patients with newly diagnosed IDH1 or IDH2 mutated AML * Not a candidate for or refuses intensive induction therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Creatinine clearance \> 40 ml/min * Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) \< 5 x upper limit of normal * Total bilirubin \< 1.5 x upper limit of normal (except for patients with Gilbert's disease) * At the time of Venetoclax initiation, white blood cells (WBC) needs to be \< 25 × 103 microliter: Hydroxyurea can be used to achieve that level. * For female patients of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the screening visit throughout the study treatment period and for 6 months following the last dose of either study drug. A serum pregnancy test will be done at screening. A serum or urine pregnancy test will be done on Day 1 of each cycle for women of childbearing potential. If the urine pregnancy test is positive, a serum pregnancy test must be performed per institutional standards. The following methods are acceptable methods of contraception for the purpose of this study: * Highly Effective Contraception Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods (Clinical Trials Facilitation Group 2014): * Combined (estrogen and progestin co…